Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04359186

SCOPE Analytic Treatment Interruption Protocol

The goal of this study is to understand the interaction between HIV and the host at the earliest stages when HIV medications are paused. Volunteers with HIV will interrupt antiretroviral therapy (ART) and then have intensive studies preformed two to three times per week. Most will resume therapy within three weeks, even if the virus does not rebound during this time.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of California San Francisco

San Francisco, California, 94110, United States

Location status: Recruiting

Location contact

Rebecca Hoh

CONTACT

[email protected]

About this study

In this study, people living with HIV will undergo intensive sampling prior to and following an interruption of their antiretroviral therapy (ART). Individuals will be asked to resume ART once the virus is detectable, or after approximately three weeks if the virus remains undetectable.

Individuals who were able to control their virus before ART ("controllers") will be able to participate in an extended treatment interruption and have less restrictive ART restart criteria.

The overall goal of the study is to characterize the interaction between the host and the virus at the earliest stages of virus replication and to identify predictors of rebound before virus becomes detectable.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Willing and able to provide written informed consent
  • Age >= 18
  • Documented HIV infection
  • Antiretroviral therapy for at least 12 months
  • Screening plasma HIV RNA levels below level of detection (< 40-75 copies/mL), and all available determinations in past 12 months also below level of detection (blips allowed)
  • Screening CD4+ T-cell count >350 cells/uL
  • If of childbearing potential, willing to use two methods of contraception
  • Willing to receive counseling regarding HIV transmission risk mitigation

Exclusion criteria

  • Pregnant or plans to become pregnant during the course of the study
  • Active hepatitis B, defined as (1) positive sAg or (2) positive cAb with negative sAb and positive HBV DNA
  • Active hepatitis C, defined as positive Hep C Ab with positive HCV RNA
  • Use of a non-nucleoside reverse transcriptase inhibitor and unable to switch regimen
  • Significant cardiovascular or cerebrovascular disease
  • Recent or prior (within past 5 years) malignancy
  • Severe kidney disease (CrCl < 50 mL/min via Cockroft-Gault method)
  • Severe hepatic impairment (Child-Pugh Class C) or unstable liver disease
  • Concurrent treatment with immunomodulatory drugs
  • Unable or unwilling to use barrier protection or pre-exposure prophylaxis (PrEP) to prevent HIV transmission with sexual partners not known to be HIV-infected

Treatment and study plan

Treatment Interruption Arm

Other

Individuals with HIV on suppressive ART will interrupt their ART.

Primary outcomes

  1. Acute retroviral syndrome

    Time frame: Week 0 through Month 6

    The proportion of participants developing acute retroviral syndrome

  2. Failure to re-suppress

    Time frame: Week 0 through Month 12

    The proportion of participants who fail to re-suppress to plasma HIV RNA levels <50 copies/mL after re-initiating ART

  3. CD4+ T cell decline

    Time frame: Week 0 through Month 6

    The proportion of participants with confirmed decreases in CD4+ T cell count below 350 cells/uL

  4. Time to rebound

    Time frame: Week 0 through Month 6

    The time between the treatment interruption and plasma HIV RNA >200 copies/mL

Study contacts

Contact information is provided by the study sponsor or research team.

Michael Peluso, MD

CONTACT

[email protected]

415-476-9363

Steven Deeks, MD

CONTACT

[email protected]

415-476-4082 ext. 404

Sponsors and collaborators

Lead sponsor

University of California, San Francisco

Other

Collaborators

  • Chan Zuckerberg Biohub

Registry information

Official study title

Analytic Treatment Interruption in HIV Infection

Acronym: SCOPE-ATI

Important dates

Study start
2020
Primary completion
2027
Study completion
2028
First posted
Apr 24, 2020
Registry last updated
Jan 23, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.